var data={"title":"Pseudomonas aeruginosa bacteremia and endocarditis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pseudomonas aeruginosa bacteremia and endocarditis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/contributors\" class=\"contributor contributor_credentials\">Souha S Kanj, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 05, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Pseudomonas aeruginosa</em> is one of the most commonly considered gram-negative aerobic bacilli in the differential diagnosis of a number of probable gram-negative infections. Consideration of this organism is important because it causes severe hospital-acquired infections, especially in immunocompromised hosts, is often antibiotic resistant, complicating the choice of therapy, and is associated with a high mortality rate.</p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of <em>P. aeruginosa</em> bacteremia and endocarditis will be reviewed here. </p><p>The general principles of antimicrobial treatment of infections caused by <em>P. aeruginosa</em>, including antibiotic options and decisions on combination therapy, are discussed in detail elsewhere. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;</a>.)</p><p>The clinical manifestations and management of other <em>P. aeruginosa</em> infections and the epidemiology and pathogenesis of infection with this organism are also discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa pneumonia&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa skin and soft tissue infections&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pseudomonas-aeruginosa-infections-of-the-eye-ear-urinary-tract-gastrointestinal-tract-and-central-nervous-system\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection#H2457284300\" class=\"medical medical_review\">&quot;Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection&quot;, section on 'Pseudomonas aeruginosa'</a> and <a href=\"topic.htm?path=cystic-fibrosis-treatment-of-acute-pulmonary-exacerbations#H1513954250\" class=\"medical medical_review\">&quot;Cystic fibrosis: Treatment of acute pulmonary exacerbations&quot;, section on 'Antibiotic selection'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">BACTEREMIA</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bloodstream infection with <em>P. aeruginosa</em> is most commonly hospital-acquired and is a problem worldwide [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/1-6\" class=\"abstract_t\">1-6</a>]. In a prospective analysis from the SCOPE (Surveillance and Control of Pathogens of Epidemiologic Importance) database of 24,179 hospital-acquired bloodstream infections occurring in 49 hospitals in the United States between 1995 to 2002, <em>Pseudomonas</em> species accounted for 4 percent of cases and were the third leading cause of gram-negative infections [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/5\" class=\"abstract_t\">5</a>]. In certain settings, such as intensive care units, the proportion of gram-negative bloodstream infections due to <em>P. aeruginosa</em> is even higher. (See <a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults#H5\" class=\"medical medical_review\">&quot;Gram-negative bacillary bacteremia in adults&quot;, section on 'Microbiology'</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-and-microbiology-of-intravascular-catheter-infections\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and microbiology of intravascular catheter infections&quot;</a>.)</p><p>Risk factors for <em>P. aeruginosa</em> bacteremia include [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/3,6-13\" class=\"abstract_t\">3,6-13</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neutropenia or other immunodeficiency (eg, hematologic malignancy, solid organ or bone marrow transplantation, or HIV infection)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Advanced age</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pancreatobiliary tract disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe burns</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indwelling central venous or urinary catheter</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimicrobial therapy within the prior three months</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Traumatic wounds that have been contaminated with fresh water</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recent hospitalization </p><p/><p>As an example, in a study of patients with hematologic malignancies, the 42 who had <em>P. aeruginosa</em> bacteremia were more likely to have had hospitalization or receipt of aminoglycosides, fluoroquinolones, or <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> in the three months preceding infection compared with 84 matched controls [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/13\" class=\"abstract_t\">13</a>]. </p><p>Hospital-acquired <em>P. aeruginosa</em> bacteremia may result from primary infection in the lungs, biliary and gastrointestinal tract, urinary tract, skin and soft tissues, or from infected intravascular catheters [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/4,14,15\" class=\"abstract_t\">4,14,15</a>]. The source of the bacteremia is unknown in up to 40 percent of cases.</p><p>Pancreatobiliary tract disease is an important risk factor for bacteremia, independent of underlying malignancy or immunosuppression [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/14\" class=\"abstract_t\">14</a>]. Pancreatobiliary sources and complications from endoscopic retrograde cholangiopancreatography (ERCP) appear to be increasing in frequency as the cause of <em>P. aeruginosa</em> bacteremia in many regions. Clusters of <em>P. aeruginosa</em> bacteremias after ERCP have been traced to inadequate cleaning or disinfection of endoscopes [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Among immunocompetent patients, <em>P. aeruginosa</em> bacteremia is largely seen in patients with indwelling urinary and central venous catheters and following traumatic or surgical wound infections [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> bacteremia does not differ clinically from bacteremia due to other gram-negative bacilli, all of which contain endotoxin, the initiator of shock in these patients. (See <a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults#H7\" class=\"medical medical_review\">&quot;Gram-negative bacillary bacteremia in adults&quot;, section on 'Clinical manifestations'</a> and <a href=\"topic.htm?path=pathophysiology-of-sepsis\" class=\"medical medical_review\">&quot;Pathophysiology of sepsis&quot;</a>.)</p><p>Bacteremic patients typically present with fever, tachycardia, and tachypnea. Disorientation, hypotension, and respiratory failure (due to either pneumonia or acute respiratory distress syndrome [ARDS]) are other common complications, especially in immunocompromised or debilitated patients. Additional clinical manifestations will vary by the site of the primary infection.</p><p>Certain patients with <em>P. aeruginosa</em> bacteremia can develop ecthyma gangrenosum (<a href=\"image.htm?imageKey=ID%2F80582\" class=\"graphic graphic_picture graphicRef80582 \">picture 1</a>), a skin lesion that results from perivascular bacterial invasion of the media and adventitia of arteries and veins with secondary ischemic necrosis. Although ecthyma gangrenosum is not pathognomonic of <em>P. aeruginosa</em> infection, the presence of these lesions should immediately raise the high probability that <em>P. aeruginosa</em> is the causative organism. This is discussed in detail elsewhere. (See <a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections#H1133434152\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa skin and soft tissue infections&quot;, section on 'Ecthyma Gangrenosum'</a>.)</p><p>Other skin lesions that may occasionally accompany pseudomonal bacteremia include: diffuse maculopapular lesions, painful clusters of small vesicles or pustules, flat sharply-demarcated areas of cellulitis that may initially mimic erysipelas and become necrotic with time, and metastatic soft tissue abscesses that may appear on the extremities and fingertips [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p>Although it is usually impossible to distinguish patients with <em>P. aeruginosa</em> bacteremia from patients with bacteremia due to other gram-negative rods based on clinical features alone, patients with <em>P. aeruginosa</em> infection are more likely to have a fatal outcome. (See <a href=\"#H8\" class=\"local\">'Prognosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prompt active antimicrobial therapy is critical in the management of <em>P. aeruginosa</em> bacteremia (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>), as delayed therapy correlates with increased mortality (see <a href=\"#H8\" class=\"local\">'Prognosis'</a> below). In certain high risk patients (eg, patients with neutropenia or severe burns) and those with severe infections (eg, patients with <span class=\"nowrap\">sepsis/shock),</span> we favor the use of combination antimicrobial therapy for empiric therapy of known or suspected <em>P. aeruginosa</em> bacteremia prior to determination of drug susceptibility. The rationale for the use of combination therapy in select situations is discussed elsewhere. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675458\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Combination antimicrobial therapy'</a>.)</p><p>Discussion of empiric therapy for gram-negative rod bacteremia and when <em>P. aeruginosa</em> should be covered is also found elsewhere. (See <a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults#H13\" class=\"medical medical_review\">&quot;Gram-negative bacillary bacteremia in adults&quot;, section on 'Empiric antimicrobial therapy'</a> and <a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults#H24171748\" class=\"medical medical_review\">&quot;Gram-negative bacillary bacteremia in adults&quot;, section on 'Indications and rationale for coverage of P. aeruginosa'</a>.) </p><p>When the isolate and results of susceptibility testing are known, antimicrobial therapy should be adjusted accordingly. In general, there is no convincing clinical evidence that using two active antipseudomonal agents offers a mortality benefit over a single active agent. This is discussed in detail elsewhere. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675708\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Rationale'</a>.)</p><p>Thus, for most patients with <em>P. aeruginosa</em> bacteremia, we suggest treatment with a single intravenous antipseudomonal antibiotic to which the isolate is susceptible (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>); aminoglycosides should not be used as a single agent. Treatment duration is largely dictated by the primary site of infection. If bacteremia is secondary to a central venous or an indwelling urinary catheter infection in a nonneutropenic host, treatment can be stopped after 7 to 10 days if the catheter has been removed and the patient has responded promptly to therapy. If the isolate is susceptible to fluoroquinolones and there are no concerns about gastrointestinal tract absorption of oral medications, the patient can transition to oral <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> or <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> to complete the course.</p><p><em>P. aeruginosa</em> bacteremia in the setting of neutropenia has been associated with a particularly high mortality, although less than previously [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/20\" class=\"abstract_t\">20</a>]. In such settings, because of the high mortality, some experts, despite the absence of data to support the practice, continue to use two intravenous antipseudomonal antibiotics from different classes to which the isolate is susceptible (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>) for the first three to five days of treatment to ensure clinical improvement. We do not do this because of the lack of supportive data and instead use a single active agent for the full course. Antimicrobial treatment should generally be continued at least 14 days or longer, until recovery of the neutrophil count. </p><p>Antipseudomonal agents and their dosing are discussed elsewhere. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H4\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p>In addition to antimicrobial therapy, the primary site of infection should also be addressed. All infected catheters should be removed, and abscesses or obstructions should be drained or removed whenever possible.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Prognosis</span></p><p class=\"headingAnchor\" id=\"H42033779\"><span class=\"h3\">Mortality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bacteremia due to <em>P. aeruginosa</em> is associated with a high mortality rate compared with bacteremia due to other gram-negative bacilli or gram-positive organisms. </p><p>One study, which prospectively compared 314 patients with bacteremia due to <em>P. aeruginosa</em> or <em>S. aureus</em>, found that mortality was significantly higher with <em>P. aeruginosa</em> than with either methicillin-susceptible <em>S. aureus</em> (MSSA) or methicillin-resistant <em>S. aureus</em> (MRSA) (30.6 percent, 16.2 percent, and 13.5 percent, respectively) [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/21\" class=\"abstract_t\">21</a>]. In a retrospective analysis of 136 patients with <em>P. aeruginosa</em> bacteremia, the 30-day mortality rate was 39 percent [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/22\" class=\"abstract_t\">22</a>]. </p><p class=\"headingAnchor\" id=\"H42033785\"><span class=\"h3\">Risk factors for poor prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mortality is especially high in neutropenic patients and in patients who present with or develop septic shock. </p><p>In a study of 133 episodes of <em>P. aeruginosa</em> bacteremia, a stepwise logistic regression analysis identified four variables as independently influencing outcome [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/23\" class=\"abstract_t\">23</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Development of septic shock</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Granulocyte count <span class=\"nowrap\">&lt;500/mm3</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inappropriate antibiotic therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Development of septic metastasis</p><p/><p>Other studies have shown that the prognosis of <em>P. aeruginosa</em> bacteremia is closely related to the underlying condition of the host and the primary site of infection. In a study of 100 episodes of <em>P. aeruginosa</em> bacteremia, survival directly correlated with underlying disease [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/24\" class=\"abstract_t\">24</a>]. Twenty-six of 47 patients (55 percent) with nonfatal underlying conditions survived, compared with 2 of 13 (15 percent) and 16 of 64 (25 percent) with rapidly fatal and ultimately fatal underlying conditions, respectively. Mortality is also usually higher when the bacteremia accompanies a pulmonary infection [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/25\" class=\"abstract_t\">25</a>].</p><p>The presence of drug resistance may also negatively impact prognosis. Two studies found that strains of <em>P. aeruginosa</em> that produce metallo-beta-lactamases or specific (PER-1) extended spectrum beta-lactamases cause unusually high mortality rates when present in the bloodstream [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/26,27\" class=\"abstract_t\">26,27</a>]. In a prospective multicenter study of 632 cases of <em>P. aeruginosa</em> bacteremia, carbapenem resistance (n = 145) was not associated with higher mortality overall (35 versus 27 percent with susceptible strains); however, in a subgroup analysis, higher 30-day mortality rates were noted among patients with few comorbidities when carbapenem resistance was present (adjusted OR 6 to 10) [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/28\" class=\"abstract_t\">28</a>]. </p><p>Other factors that have been associated with poor prognosis include the presence of polymicrobial (versus monomicrobial bacteremia) and advanced age [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/22,29,30\" class=\"abstract_t\">22,29,30</a>]. In a study of patients with hematologic malignancies who had <em>Pseudomonas</em> infections, hypophosphatemia, hypoproteinemia, and high serum lactate were associated with an increased risk of septic shock on multivariate analysis [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H42033811\"><span class=\"h3\">Effect of antimicrobial therapy on prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice and timing of antibiotic therapy is particularly crucial. As an example, in one study of 410 episodes of <em>P. aeruginosa</em> bacteremia, cure was substantially higher in patients receiving appropriate antibiotics than in those who did not (67 versus 14 percent), and a one- to two-day delay in administering appropriate antibiotics reduced the cure rate from 74 to 46 percent [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/32\" class=\"abstract_t\">32</a>]. In one prospective ICU study, inadequate antimicrobial therapy was statistically associated with a higher mortality rate (62 versus 28 percent, RR 2.18, 95 percent CI 5.09-9.24, p&lt;0.001) [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/33\" class=\"abstract_t\">33</a>]. Approximately 10 percent of patients in this study had <em>P. aeruginosa</em> bacteremia.</p><p>The prognosis of <em>P. aeruginosa</em> bacteremia in neutropenic patients with hematologic malignancies has subsequently improved [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/34\" class=\"abstract_t\">34</a>]. One retrospective study showed an improved prognosis of <em>P. aeruginosa</em> bacteremia in the years 1992 to 1996 compared with 1976 to 1982 [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/20\" class=\"abstract_t\">20</a>]. This improvement was due mainly to changes in the management of the infection:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>More frequent use of new anti-pseudomonal beta-lactams and <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> instead of aminoglycosides as monotherapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prompt removal of catheters.</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">ENDOCARDITIS</span></p><p class=\"headingAnchor\" id=\"H296144973\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infective endocarditis (IE) due to <em>P. aeruginosa</em> is uncommon, but when it occurs, it is strongly associated with intravenous drug use (IVDU) <span class=\"nowrap\">and/or</span> prosthetic heart valves [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/35\" class=\"abstract_t\">35</a>] and pacemakers. More than 90 percent of cases of IE due to <em>P. aeruginosa</em> have been reported in IVDU, and most patients had no previous structural heart disease. <em>P. aeruginosa</em> IE tends to occur in specific geographic locations; epidemics of this infection have been described in IVDU, mainly users of <a href=\"topic.htm?path=pentazocine-drug-information\" class=\"drug drug_general\">pentazocine</a> and tripelennamine, presumably associated with mixing of drugs in contaminated water [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/36,37\" class=\"abstract_t\">36,37</a>]. </p><p><em>P. aeruginosa</em> is also an occasional cause of hospital-acquired endocarditis, accounting for 10 percent of cases in one small ICU series [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, the clinical manifestations of IE are similar whether due to <em>P. aeruginosa</em> or other organisms. However, given the close association with IVDU, the most frequently involved valve is the tricuspid. Additionally, multiple valve involvement can occur. In a study of 34 cases from one center, 13 had isolated involvement of the tricuspid valve and an additional case had tricuspid and pulmonic valve infection [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/39\" class=\"abstract_t\">39</a>]. </p><p>Since tricuspid infection is common, many patients present with pulmonary manifestations, including cough, chest pain, and hemoptysis. Such patients often have multiple discrete lung lesions that may progress to cavitation. Patients with left-sided valvular infections often develop fulminant or rapidly progressive symptoms that are due to either congestive heart failure or embolism of large or medium-sized arteries. Ring and annular abscesses are also frequent complications [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/39\" class=\"abstract_t\">39</a>].</p><p>Patients with tricuspid valve infection typically have a less fulminant course and better prognosis than patients with left-sided valvular involvement. In one study, 20 of 25 patients with right-sided infection recovered with medical or combined <span class=\"nowrap\">medical/surgical</span> therapy compared with only three of nine patients with left-sided infection [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/40\" class=\"abstract_t\">40</a>].</p><p>The clinical manifestations of endocarditis are discussed in detail elsewhere. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-adults-with-suspected-native-valve-endocarditis\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of adults with suspected native valve endocarditis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the setting of <em>P. aeruginosa</em> bacteremia, the diagnosis of endocarditis can be made with echocardiography and application of the Duke Criteria for endocarditis. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-adults-with-suspected-native-valve-endocarditis\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of adults with suspected native valve endocarditis&quot;</a>.)</p><p>The vast majority of patients with <em>P. aeruginosa</em> bacteremia do not have IE, and even those patients who have underlying risk factors for IE, such as patients with prosthetic heart valves, can have <em>P. aeruginosa</em> bacteremia in association with a urinary tract or wound infection. Thus, it would be impractical and of low yield to perform echocardiography in all patients with <em>P. aeruginosa</em> bacteremia. We evaluate for IE among patients with <em>P. aeruginosa</em> bacteremia in the following settings:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Failure to clear bloodstream infection on appropriate therapy</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of other stigmata of IE, including new regurgitant murmurs or evidence of embolic disease to the periphery, lungs, or central nervous system</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of underlying conditions increasing the risk of IE, including intravenous drug use, prosthetic valve, and a previous history of endocarditis</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of <em>P. aeruginosa</em> IE usually necessitates the combination of antibiotics and surgery to achieve cure [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/2\" class=\"abstract_t\">2</a>]. This is based on the fact that beta-lactam antibiotics have a slow onset of bactericidal activity against the organism, lack a postantibiotic effect, and can rapidly induce the development of resistance.</p><p>For antimicrobial therapy of <em>P. aeruginosa</em> IE, we suggest combination therapy with two intravenous antipseudomonal antibiotics from different classes to which the isolate is susceptible (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>); one antibiotic should be an aminoglycoside unless the use is precluded by nephrotoxicity. The duration of therapy should be for at least six weeks. There are essentially no data comparing combination to monotherapy for <em>P. aeruginosa</em> IE, as it is a relatively uncommon infection; the vast majority of the published literature describes treatment with a combination antimicrobial regimen [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/37,41\" class=\"abstract_t\">37,41</a>]. Specific antipseudomonal agents and their doses are discussed elsewhere. (See <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H4\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p>We routinely obtain early surgical consultation in all cases of <em>P. aeruginosa</em> endocarditis because of the association of improved prognosis with early valve replacement, particularly in the setting of left-sided disease (see <a href=\"#H13\" class=\"local\">'Prognosis'</a> below). When splenic abscesses complicate <em>P. aeruginosa</em> IE, splenectomy should be performed prior to valve replacement. </p><p>Tricuspid <span class=\"nowrap\">and/or</span> pulmonic valvulectomy without immediate replacement is indicated in patients with right-sided endocarditis who remain bacteremic after two weeks of therapy or relapse after a six-week course [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/42,43\" class=\"abstract_t\">42,43</a>]. This procedure has an 80 percent success rate and can be followed by tricuspid valve replacement six to eight months later. </p><p>Additional surgical issues for native and prosthetic valve endocarditis are discussed elsewhere. (See <a href=\"topic.htm?path=surgery-for-left-sided-native-valve-infective-endocarditis\" class=\"medical medical_review\">&quot;Surgery for left-sided native valve infective endocarditis&quot;</a> and <a href=\"topic.htm?path=surgery-for-prosthetic-valve-endocarditis\" class=\"medical medical_review\">&quot;Surgery for prosthetic valve endocarditis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>P. aeruginosa</em> endocarditis is associated with a poor outcome. In one study in patients with <em>S. aureus</em> and <em>P. aeruginosa</em> bacteremia, endocarditis was found to be an independent determinant of hospital mortality (OR 4.62; 95 percent CI 2.45-8.73) [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/21\" class=\"abstract_t\">21</a>].</p><p>In patients with left-sided IE due to <em>P. aeruginosa</em>, the prognosis for medical therapy is worse than for combined medical and surgical therapy [<a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/36,37\" class=\"abstract_t\">36,37</a>]. Early valve replacement has been shown to improve prognosis and is indicated in cases refractory to medical treatment and in complicated cases with hemodynamic instability. (See <a href=\"topic.htm?path=surgery-for-left-sided-native-valve-infective-endocarditis\" class=\"medical medical_review\">&quot;Surgery for left-sided native valve infective endocarditis&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H1672613594\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-treatment-and-prevention-of-infective-endocarditis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Treatment and prevention of infective endocarditis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H296145128\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Pseudomonas aeruginosa</em> is one of the most commonly considered gram-negative aerobic bacilli in the differential diagnosis of a number of probable gram-negative infections. Consideration of this organism is important because it causes severe hospital-acquired infections, especially in immunocompromised hosts, is often antibiotic resistant, complicating the choice of therapy, and is associated with a high mortality rate. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p class=\"headingAnchor\" id=\"H296145101\"><span class=\"h2\">Bacteremia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bloodstream infection with <em>P. aeruginosa</em> is most commonly hospital-acquired. Risk factors for <em>P. aeruginosa</em> bacteremia include neutropenia or other immunodeficiency (eg, hematologic malignancy, solid organ or bone marrow transplantation, or HIV infection), advanced age, pancreatobiliary tract disease, severe burns, an indwelling central venous or urinary catheter, antimicrobial therapy within the last 30 days, and traumatic wounds that have been contaminated with fresh water. (See <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hospital-acquired <em>P. aeruginosa</em> bacteremia may result from primary infection in the lungs, biliary and gastrointestinal tract, urinary tract, skin and soft tissues or from infected intravascular catheters. (See <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacteremic patients typically present with fever, tachycardia, and tachypnea. Disorientation, hypotension, and respiratory failure due to either pneumonia or acute respiratory distress syndrome are other common complications, especially in immunocompromised or debilitated patients. Although it is usually impossible to distinguish patients with <em>P. aeruginosa</em> bacteremia from patients with bacteremia due to other gram-negative rods on clinical grounds alone, patients with <em>P. aeruginosa</em> infection are more likely to have a fatal outcome and to develop ecthyma gangrenosum. The lesions of ecthyma gangrenosum (<a href=\"image.htm?imageKey=ID%2F80582\" class=\"graphic graphic_picture graphicRef80582 \">picture 1</a>) involve the skin or mucous membranes, beginning as a small area of edema and quickly evolving into painless nodular lesions with central hemorrhage, ulceration, and necrosis. (See <a href=\"#H4\" class=\"local\">'Clinical features'</a> above and <a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections#H1133434152\" class=\"medical medical_review\">&quot;Pseudomonas aeruginosa skin and soft tissue infections&quot;, section on 'Ecthyma Gangrenosum'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prompt empiric therapy with an active antimicrobial agent (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>) is critical in the management of known or suspected <em>P. aeruginosa</em> bacteremia, as delayed therapy correlates with increased mortality. In certain high risk patients (eg, patients with neutropenia or severe burns) and those with severe infections (eg, patients with <span class=\"nowrap\">sepsis/shock),</span> we favor the use of combination antimicrobial therapy for empiric therapy. Otherwise, a single antipseudomonal agent is likely appropriate. In addition, infected catheters should be removed, and abscesses or obstructions should be drained or removed, whenever possible. The rationale for combination therapy in select settings is discussed elsewhere. (See <a href=\"#H7\" class=\"local\">'Treatment'</a> above and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H371759579\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Indications for combination therapy'</a> and <a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults#H13\" class=\"medical medical_review\">&quot;Gram-negative bacillary bacteremia in adults&quot;, section on 'Empiric antimicrobial therapy'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When the isolate and results of susceptibility testing are known, antimicrobial therapy should be adjusted accordingly. In general, there is no clinical evidence that using two active antipseudomonal agents offers a mortality benefit over a single active agent. (See <a href=\"#H7\" class=\"local\">'Treatment'</a> above and <a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections#H6675458\" class=\"medical medical_review\">&quot;Principles of antimicrobial therapy of Pseudomonas aeruginosa infections&quot;, section on 'Combination antimicrobial therapy'</a>.)</p><p/><p class=\"bulletIndent1\">Thus, for most patients with <em>P. aeruginosa</em> bacteremia, we suggest treatment with a single intravenous antipseudomonal antibiotic to which the isolate is susceptible instead of a combination antimicrobial regimen (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Aminoglycosides should not be used as a single agent. However, because of the high associated mortality rate of <em>P. aeruginosa</em> bacteremia in the setting of neutropenia, it is reasonable to continue a second active antipseudomonal agent for the first three to five days of treatment of neutropenic patients pending clinical improvement.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacteremia due to <em>P. aeruginosa</em> is associated with a high mortality rate compared with bacteremia due to other gram-negative bacilli as well as gram-positive organisms. (See <a href=\"#H8\" class=\"local\">'Prognosis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H296145136\"><span class=\"h2\">Endocarditis</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infective endocarditis (IE) due to <em>P. aeruginosa</em> is uncommon, but when it occurs, it is strongly associated with intravenous drug use (IVDU) <span class=\"nowrap\">and/or</span> prosthetic heart valves and pacemakers. (See <a href=\"#H296144973\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Given the close association with IVDU, the most frequently involved valve is the tricuspid valve. Additionally, multiple valve involvement can occur. Since tricuspid infection is common, many patients present with pulmonary manifestations, including cough, chest pain, and hemoptysis. Patients with left-sided valvular infections often develop fulminant or rapidly progressive symptoms that are due to either congestive heart failure or embolism of large or medium-sized arteries. Ring and annular abscesses are also frequent complications. (See <a href=\"#H10\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the setting of <em>P. aeruginosa</em> bacteremia, the diagnosis of endocarditis can be made with echocardiography and application of the Duke Criteria for endocarditis. The vast majority of patients with <em>P. aeruginosa</em> bacteremia do not have infective endocarditis. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-adults-with-suspected-native-valve-endocarditis\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of adults with suspected native valve endocarditis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with <em>P. aeruginosa</em> infective endocarditis, we suggest combination antimicrobial therapy for the duration of the treatment course (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This regimen should include two antipseudomonal antibiotics from different classes to which the isolate is susceptible (<a href=\"image.htm?imageKey=ID%2F91115\" class=\"graphic graphic_table graphicRef91115 \">table 1</a>). (See <a href=\"#H12\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest early<strong> </strong>surgical consultation in all cases of <em>P. aeruginosa</em> endocarditis because of the association of improved prognosis with early valve replacement (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Particularly in patients with left-sided disease, the prognosis for medical therapy is worse than for combined medical and surgical therapy. (See <a href=\"#H12\" class=\"local\">'Treatment'</a> above and <a href=\"#H13\" class=\"local\">'Prognosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/1\" class=\"nounderline abstract_t\">Al-Hasan MN, Wilson JW, Lahr BD, et al. Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. Am J Med 2008; 121:702.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/2\" class=\"nounderline abstract_t\">National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996; 24:380.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/3\" class=\"nounderline abstract_t\">Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156:2121.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/4\" class=\"nounderline abstract_t\">Sifuentes-Osornio J, Gonzalez R, Ponce-de-Leon A, Guerrero ML. Epidemiology and prognosis of Pseudomonas aeruginosa bacteremia in a tertiary care center. Rev Invest Clin 1998; 50:383.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/5\" class=\"nounderline abstract_t\">Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/6\" class=\"nounderline abstract_t\">Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/7\" class=\"nounderline abstract_t\">Schechner V, Nobre V, Kaye KS, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis 2009; 48:580.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/8\" class=\"nounderline abstract_t\">Mendelson MH, Gurtman A, Szabo S, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994; 18:886.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/9\" class=\"nounderline abstract_t\">Shepp DH, Tang IT, Ramundo MB, Kaplan MK. Serious Pseudomonas aeruginosa infection in AIDS. J Acquir Immune Defic Syndr 1994; 7:823.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/10\" class=\"nounderline abstract_t\">Leigh L, Stoll BJ, Rahman M, McGowan J Jr. Pseudomonas aeruginosa infection in very low birth weight infants: a case-control study. Pediatr Infect Dis J 1995; 14:367.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/11\" class=\"nounderline abstract_t\">Dropulic LK, Leslie JM, Eldred LJ, et al. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J Infect Dis 1995; 171:930.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/12\" class=\"nounderline abstract_t\">Sorvillo F, Beall G, Turner PA, et al. Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. Am J Infect Control 2001; 29:79.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/13\" class=\"nounderline abstract_t\">Vuotto F, Berthon C, Lemaitre N, et al. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study. Am J Infect Control 2013; 41:527.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/14\" class=\"nounderline abstract_t\">Chen SC, Lawrence RH, Byth K, Sorrell TC. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor? Med J Aust 1993; 159:592.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/15\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Pseudomonas aeruginosa infections associated with transrectal ultrasound-guided prostate biopsies--Georgia, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:776.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/16\" class=\"nounderline abstract_t\">Classen DC, Jacobson JA, Burke JP, et al. Serious Pseudomonas infections associated with endoscopic retrograde cholangiopancreatography. Am J Med 1988; 84:590.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/17\" class=\"nounderline abstract_t\">Healey LA, Backes MB. Nitritoid reactions and angiotensin-converting-enzyme inhibitors. N Engl J Med 1989; 321:763.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/18\" class=\"nounderline abstract_t\">Roberts R, Tarpay MM, Marks MI, Nitschke R. Erysipelaslike lesions and hyperesthesia as manifestations of Pseudomonas aeruginosa sepsis. JAMA 1982; 248:2156.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/19\" class=\"nounderline abstract_t\">FORKNER CE Jr, FREI E 3rd, EDGCOMB JH, UTZ JP. Pseudomonas septicemia; observations on twenty-three cases. Am J Med 1958; 25:877.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/20\" class=\"nounderline abstract_t\">Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/21\" class=\"nounderline abstract_t\">Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004; 125:607.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/22\" class=\"nounderline abstract_t\">Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/23\" class=\"nounderline abstract_t\">Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1988; 10:629.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/24\" class=\"nounderline abstract_t\">Baltch AL, Hammer M, Smith RP, Sutphen N. Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance. J Lab Clin Med 1979; 94:201.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/25\" class=\"nounderline abstract_t\">Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/26\" class=\"nounderline abstract_t\">Marra AR, Pereira CA, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006; 50:388.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/27\" class=\"nounderline abstract_t\">Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/28\" class=\"nounderline abstract_t\">Pe&ntilde;a C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012; 56:1265.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/29\" class=\"nounderline abstract_t\">Aliaga L, Mediavilla JD, Llos&aacute; J, et al. Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2000; 19:871.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/30\" class=\"nounderline abstract_t\">Scheetz MH, Hoffman M, Bolon MK, et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis 2009; 64:311.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/31\" class=\"nounderline abstract_t\">Jeddi R, Gh&eacute;dira H, Ben Amor R, et al. Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections. Hematology 2011; 16:160.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/32\" class=\"nounderline abstract_t\">Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/33\" class=\"nounderline abstract_t\">Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/34\" class=\"nounderline abstract_t\">Todeschini G, Franchini M, Tecchio C, et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 1998-1999; 3:99.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/35\" class=\"nounderline abstract_t\">Reyes MP, Palutke WA, Wylin RF. Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972. Medicine (Baltimore) 1973; 52:173.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/36\" class=\"nounderline abstract_t\">Wieland M, Lederman MM, Kline-King C, et al. Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature. Medicine (Baltimore) 1986; 65:180.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/37\" class=\"nounderline abstract_t\">Reyes MP, Ali A, Mendes RE, Biedenbach DJ. Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008. Medicine (Baltimore) 2009; 88:294.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/38\" class=\"nounderline abstract_t\">Gou&euml;llo JP, Asfar P, Brenet O, et al. Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases. Crit Care Med 2000; 28:377.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/39\" class=\"nounderline abstract_t\">Komshian SV, Tablan OC, Palutke W, Reyes MP. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis 1990; 12:693.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/40\" class=\"nounderline abstract_t\">Reyes MP, Lerner AM. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis 1983; 5:314.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/41\" class=\"nounderline abstract_t\">Dawson NL, Brumble LM, Pritt BS, et al. Left-sided Pseudomonas aeruginosa endocarditis in patients without injection drug use. Medicine (Baltimore) 2011; 90:250.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/42\" class=\"nounderline abstract_t\">Arbulu A, Holmes RJ, Asfaw I. Tricuspid valvulectomy without replacement. Twenty years' experience. J Thorac Cardiovasc Surg 1991; 102:917.</a></li><li><a href=\"https://www.uptodate.com/contents/pseudomonas-aeruginosa-bacteremia-and-endocarditis/abstract/43\" class=\"nounderline abstract_t\">Robin E, Belamaric J, Thoms NW, et al. Consequences of total tricuspid valvulectomy without prosthetic replacement in treatment of Pseudomonas endocarditis. J Thorac Cardiovasc Surg 1976; 68:461.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2136 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H296145128\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">BACTEREMIA</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Epidemiology</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Clinical features</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Treatment</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Prognosis</a><ul><li><a href=\"#H42033779\" id=\"outline-link-H42033779\">- Mortality</a></li><li><a href=\"#H42033785\" id=\"outline-link-H42033785\">- Risk factors for poor prognosis</a></li><li><a href=\"#H42033811\" id=\"outline-link-H42033811\">- Effect of antimicrobial therapy on prognosis</a></li></ul></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">ENDOCARDITIS</a><ul><li><a href=\"#H296144973\" id=\"outline-link-H296144973\">Epidemiology</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Clinical features</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Diagnosis</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Treatment</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Prognosis</a></li></ul></li><li><a href=\"#H1672613594\" id=\"outline-link-H1672613594\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H296145128\" id=\"outline-link-H296145128\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H296145101\" id=\"outline-link-H296145101\">Bacteremia</a></li><li><a href=\"#H296145136\" id=\"outline-link-H296145136\">Endocarditis</a></li></ul></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2136|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/80582\" class=\"graphic graphic_picture\">- Ecthyma gangrenosum</a></li></ul></li><li><div id=\"ID/2136|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/91115\" class=\"graphic graphic_table\">- Antibiotics used for the treatment of P. aeruginosa infections</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-adults-with-suspected-native-valve-endocarditis\" class=\"medical medical_review\">Clinical manifestations and evaluation of adults with suspected native valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection\" class=\"medical medical_review\">Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-treatment-of-acute-pulmonary-exacerbations\" class=\"medical medical_review\">Cystic fibrosis: Treatment of acute pulmonary exacerbations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-and-pathogenesis-of-pseudomonas-aeruginosa-infection\" class=\"medical medical_review\">Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-microbiology-of-intravascular-catheter-infections\" class=\"medical medical_review\">Epidemiology, pathogenesis, and microbiology of intravascular catheter infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults\" class=\"medical medical_review\">Gram-negative bacillary bacteremia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-sepsis\" class=\"medical medical_review\">Pathophysiology of sepsis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=principles-of-antimicrobial-therapy-of-pseudomonas-aeruginosa-infections\" class=\"medical medical_review\">Principles of antimicrobial therapy of Pseudomonas aeruginosa infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-infections-of-the-eye-ear-urinary-tract-gastrointestinal-tract-and-central-nervous-system\" class=\"medical medical_review\">Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-pneumonia\" class=\"medical medical_review\">Pseudomonas aeruginosa pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pseudomonas-aeruginosa-skin-and-soft-tissue-infections\" class=\"medical medical_review\">Pseudomonas aeruginosa skin and soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-treatment-and-prevention-of-infective-endocarditis\" class=\"medical medical_society_guidelines\">Society guideline links: Treatment and prevention of infective endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgery-for-left-sided-native-valve-infective-endocarditis\" class=\"medical medical_review\">Surgery for left-sided native valve infective endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgery-for-prosthetic-valve-endocarditis\" class=\"medical medical_review\">Surgery for prosthetic valve endocarditis</a></li></ul></div></div>","javascript":null}